Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
40.9 HKD | -1.56% | +7.63% | +1.49% |
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+1.49% | 1.98B | - | ||
-3.43% | 184B | C+ | ||
-1.81% | 107B | C | ||
-4.15% | 67.78B | A | ||
+1.43% | 50.66B | B- | ||
+11.60% | 47.64B | B- | ||
+4.60% | 41.12B | B+ | ||
+3.03% | 26.3B | B | ||
+3.21% | 26.04B | A- | ||
+15.06% | 25.4B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 6826 Stock
- Ratings Shanghai Haohai Biological Technology Co., Ltd.